NextCell Pharma Q2 2024/2025: No cow on the ice - Redeye

Redeye updates its view on NextCell following an uneventful Q2 2024/2025 report and the company’s operational update, which offered new perspectives on recent data and subsidiary developments. While making minor revisions to our estimates, we maintain our view of the case.

Länk till analysen i sin helhet: https://www.redeye.se/research/1097110/nextcell-pharma-q2-2024-2025-no-cow-on-the-ice?utm_source=finwire&utm_medium=RSS